SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024

Feb 20 2024
BOSTON and ROLLE, Switzerland, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full-year 2023 before U.S.

Read more

Build something bigger than your career

Enjoyed learning about life at SOPHiA from our blogs? Here are a few of our open roles

Title Country Department
IVDR Expert (Regulatory Affairs) Switzerland. United Kingdom. United States Regulatory & Quality
Subject Matter Expert - APAC Malaysia. Singapore Clinical Sales
Senior Director, Clinical & BioPharma Operations Switzerland Medical
Sr Manager, Genomic Implementation Solutions United States Clinical Sales
Deal Desk and Commercial Operations Manager Switzerland. United States Clinical Sales